A Randomized Trial of Prenatal versus Postnatal Repair of Myelomeningocele
Source: View publication →
Prenatal in utero surgery for fetal myelomeningocele significantly reduced the need for cerebrospinal fluid shunting and improved motor function at 30 months compared to standard postnatal repair, though it increased maternal and fetal risks such as preterm delivery.
Key Findings
Study Design
Study Limitations
Clinical Significance
The MOMS trial firmly established open maternal-fetal surgery as a standard-of-care option for eligible pregnancies complicated by myelomeningocele. It validated the 'two-hit hypothesis,' proving that early intrauterine surgical closure mitigates ongoing secondary neurologic injury caused by prolonged exposure of the spinal cord to amniotic fluid, substantially improving long-term functional independence.
Historical Context
Prior to the MOMS trial, the in utero repair of myelomeningocele was gaining traction based on animal models and early observational human data, which suggested neurological benefit. However, the practice remained highly controversial due to the profound risks imposed on the mother and the lack of rigorous, randomized data. Sponsored by the NICHD, the MOMS trial halted unregulated, unproven procedures and definitively demonstrated the therapeutic value and specific risks of fetal surgery compared to traditional postnatal closure.
Guided Discussion
High-yield insights from every perspective
The MOMS trial demonstrates improved outcomes with prenatal repair based on the two-hit hypothesis of myelomeningocele. What are the two hits in this pathophysiologic model, and how does in utero closure prevent secondary complications like Chiari II malformation?
Key Response
The first hit is the primary embryologic failure of neural tube closure. The second hit involves ongoing chemical toxicity from amniotic fluid and mechanical trauma to the exposed spinal cord. Reversing the CSF leak by closing the defect in utero restores normal pressure dynamics, which prevents or reverses hindbrain herniation (Chiari II) that disrupts normal CSF flow, thereby directly reducing the infant's need for ventriculoperitoneal shunting.
While counseling a patient at 20 weeks gestation with a newly diagnosed fetal myelomeningocele, how should you balance the fetal benefits of prenatal repair demonstrated in the MOMS trial against the specific maternal and obstetric risks?
Key Response
Residents must master informed consent for complex interventions. Prenatal repair improves infant motor function and halves the need for shunting (40 percent versus 82 percent), but it significantly increases maternal risks such as preterm birth, uterine dehiscence, and placental abruption. It also mandates cesarean delivery for the index and all future pregnancies due to the classical hysterotomy required for the fetal repair.
The MOMS trial had strict inclusion criteria, such as an upper boundary of 25 weeks and 6 days gestation and specific anatomical lesion limitations. How do lesion level and the presence of severe kyphosis impact the technical feasibility and functional outcomes of fetal repair, and why are these criteria critical for maternal-fetal triage?
Key Response
Fetal surgery requires an optimal window before irreversible neural damage occurs, but late enough for technical feasibility. Severe kyphosis makes primary skin closure nearly impossible without extensive dissection, risking severe fetal blood loss. Higher anatomical lesions often have worse baseline functional prognoses, which fundamentally alters the risk-benefit ratio for exposing a healthy mother to major abdominal surgery and lifelong obstetric risks.
The MOMS trial shifted the paradigm of myelomeningocele management, yet creating a fetal surgery program requires immense specialized resources. As an attending, how do you navigate the centralization of fetal surgery centers and coordinate the complex long-term multidisciplinary care required for these children post-delivery?
Key Response
Fetal surgery is high-risk and high-resource, necessitating referral to specialized quaternary centers to replicate the trial safety profile. However, post-delivery and early childhood care involving pediatric neurosurgery, urology, orthopedics, and developmental pediatrics must often be transitioned back to the patient's local community. This highlights the critical importance of robust care-coordination and standardized transition protocols to maintain the initial surgical gains.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MOMS trial was stopped early by the Data and Safety Monitoring Board after 183 of the planned 200 patients were randomized due to significant efficacy in the primary outcome. What are the methodological risks of stopping a surgical trial early for efficacy, particularly concerning the accurate estimation of rare maternal adverse events?
Key Response
Stopping early for efficacy can exaggerate treatment effects due to random highs and prematurely truncate the collection of crucial safety data. For a highly invasive procedure with severe risks like uterine rupture, a smaller sample size limits the precision of confidence intervals for rare, catastrophic maternal complications, which complicates comprehensive long-term risk modeling and maternal counseling.
The trial utilized highly experienced surgeons at only three established quaternary centers. If reviewing a follow-up multi-center implementation study, what methodological safeguards would you require to ensure that the surgical learning curve and outcomes in newly adopting non-trial centers do not mask increased maternal and fetal morbidity?
Key Response
The positive MOMS effect relies heavily on the expertise of highly specific, multidisciplinary surgical teams. A discerning editor must be highly critical of generalizability; widespread adoption without rigorous credentialing, mandatory registry tracking, and strict quality assurance can easily lead to unacceptably high maternal-fetal morbidity that was successfully mitigated in the tightly controlled trial environment.
Based on the MOMS trial results, ACOG and SMFM guidelines now recommend that maternal-fetal surgery for myelomeningocele be offered as an option to eligible patients. What level of evidence supports this, and what specific institutional and resource criteria must guidelines mandate to safely integrate this procedure into standard obstetric practice?
Key Response
Supported by Level A evidence from this well-conducted RCT, guidelines mandate that this option be discussed with eligible families. However, ACOG/SMFM guidelines strongly emphasize that the procedure should only be performed at multidisciplinary centers with extensive fetal surgery experience, specialized obstetric anesthesia, and high-risk NICU capabilities to strictly mitigate the substantial known risks of extreme prematurity, maternal hemorrhage, and uterine rupture.
Clinical Landscape
Noteworthy Related Trials
MRC Vitamin Study
Tested
Folic acid supplementation (4 mg daily)
Population
Women with a prior pregnancy affected by a neural tube defect
Comparator
Placebo or vitamins without folic acid
Endpoint
Incidence of neural tube defects in the subsequent pregnancy
Eurofoetus Trial
Tested
Fetoscopic laser coagulation of chorionic vessels
Population
Pregnant women with severe twin-twin transfusion syndrome
Comparator
Serial amnioreduction
Endpoint
Survival of at least one twin to 28 days of age and survival without neurologic complications at 6 months
TOTAL Trial
Tested
Fetoscopic endoluminal tracheal occlusion (FETO)
Population
Fetuses with severe isolated congenital diaphragmatic hernia
Comparator
Expectant management with postnatal repair
Endpoint
Survival to discharge from the neonatal intensive care unit
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis